<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216030</url>
  </required_header>
  <id_info>
    <org_study_id>1267-USAI-000-ETH-01</org_study_id>
    <nct_id>NCT04216030</nct_id>
  </id_info>
  <brief_title>IP Peru, Bioavailability of Iron From Potatoes</brief_title>
  <acronym>IPPERU</acronym>
  <official_title>Iron Bioavailability From Iron Bio-fortified Irish Potato in Peruvian Women Between 18-25 Years of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Federal Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genetics, Genomics and Crop Improvement Program, International Potato Center, Lima, Peru</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quadram Institute Bioscience</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Investigacion Nutricional, Lima, Peru</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Federal Institute of Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To combat iron deficiency in Low and Middle-Income Countries, sustainable food-based&#xD;
      solutions have to be implemented to serve populations, not only individuals. One solution is&#xD;
      the introduction of iron biofortified staple crops on market level. Before market level&#xD;
      introduction, the bioavailability of iron in the new biofortified Irish Potato (IP) breed&#xD;
      needs to be assessed. In this study the investigator compares the fractional and total iron&#xD;
      absorption after extrinsic stable isotope labelling of the new biofortified high iron IP&#xD;
      variety and a normal market level IP variety. The study is conducted in Peruvian women of&#xD;
      reproductive age with marginal iron status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 40 women enrolled will consume test meals consisting of 500g steamed and mashed high iron&#xD;
      Irish potatoes labelled with Fe-58 daily for a period of 10 days and will then switch to the&#xD;
      test meals consisting of 400g steamed and mashed control sweet potatoes labelled with Fe-57&#xD;
      for a period of 10 days. The order of test meal type is random. A baseline blood sample will&#xD;
      be taken on the first meal feeding day prior to consumption of any test meals, study day 15&#xD;
      (before switching to the other test meal IP variety), on study day 26 (14 days after&#xD;
      completion of the first test meal period) and on Day 40 (14 days after completion of the&#xD;
      second test meal period). Erythrocyte incorporation of the stable isotope labels will be&#xD;
      measured in these blood samples using an ICPMS and will be used to calculate fractional and&#xD;
      total iron absorption from the two different type of test meals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2019</start_date>
  <completion_date type="Actual">August 8, 2019</completion_date>
  <primary_completion_date type="Actual">August 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each woman consumes both high-iron Irish potato and a regular Irish potato variety.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Participant is non-blinded based on differences in meal option A and B, meal option A --&gt; B or B --&gt; A, is assigned through investigator randomisation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional iron absorption from both Irish Potato test meals</measure>
    <time_frame>Measured 2 weeks after completion of feeding day sequence. Sequence consist of 2 times 10 feeding days.</time_frame>
    <description>Proportion of stable isotope administered with test meals that has been incorporate into erythrocytes 14 days after completion of specific test meal feeding period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total iron absorption from both Irish Potato test meals</measure>
    <time_frame>Measured 2 weeks after completion of feeding day sequence. Sequence consist of 2 times 10 feeding days.</time_frame>
    <description>Amount of iron absorbed (mg) from the labelled test meals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of plasma ferritin level</measure>
    <time_frame>screening (-1), day 1 (baseline), day 15 (before switch to other test meal type) day 26 (last feeding day) and day 40 (14 days after last test meal consumption).</time_frame>
    <description>Iron status marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of plasma CRP level</measure>
    <time_frame>screening (-1), day 1 (baseline), day 15 (before switch to other test meal type) day 26 (last feeding day) and day 40 (14 days after last test meal consumption).</time_frame>
    <description>Inflammation status marker</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Iron-deficiency</condition>
  <condition>Iron Deficiency Anemia</condition>
  <condition>Iron Deficiency (Without Anemia)</condition>
  <arm_group>
    <arm_group_label>High iron Irish potato</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meal sequence B, IP High Fe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular Irish potato</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meal sequence A, OFSP control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High Fe IP meal labelled with Fe-58</intervention_name>
    <description>500 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days</description>
    <arm_group_label>High iron Irish potato</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control OFSP meal labelled with Fe-57</intervention_name>
    <description>500 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days</description>
    <arm_group_label>Regular Irish potato</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Woman aged 18-25 years old.&#xD;
&#xD;
          2. Low/marginal iron status: serum ferritin (SF) ≤ 25 μg/L.&#xD;
&#xD;
          3. Normal BMI for age (18.5-25.0 kg/m2).&#xD;
&#xD;
          4. Weight less than 65 kg. We will give equal amounts of stable isotopes to each study&#xD;
             participant and therefore need to set a limit on body weight in order to achieve&#xD;
             measurable isotope enrichment in erythrocytes.&#xD;
&#xD;
          5. Willing and able to commute to the meal distribution/health centre site.&#xD;
&#xD;
          6. Able to understand and to sign written concept prior to trial entry.&#xD;
&#xD;
          7. Informed consent signed.&#xD;
&#xD;
          8. Prepared to use contraceptives for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe anaemia Hb &lt;107.2 g/L (adjusted for meters above sea level)&#xD;
&#xD;
          2. Inflammation/infection (CRP &gt; 5 mg/100 ml).&#xD;
&#xD;
          3. Relevant digestive (intestinal, gastric, hepatic or pancreatic), renal, metabolic&#xD;
             disease, and any other problem that will interfere with the study as determined by the&#xD;
             screening visit and by self-report from the subjects.&#xD;
&#xD;
          4. Pregnant (urine test before entering the study) or breast-feeding.&#xD;
&#xD;
          5. Any medication or supplement which may impact iron metabolism.&#xD;
&#xD;
          6. Unwilling to discontinue vitamin and minerals supplements at least two weeks prior to&#xD;
             the study start, as ascertained at the screening visit.&#xD;
&#xD;
          7. Significant blood losses over the past 6 months (i.e. trauma, major surgery, blood&#xD;
             donation).&#xD;
&#xD;
          8. Subject who cannot be expected to comply with study procedures.&#xD;
&#xD;
          9. Presence of fever (&gt;37.5 °C) on the first study day&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reyna Liria</last_name>
    <role>Principal Investigator</role>
    <affiliation>INN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Penny</last_name>
    <role>Principal Investigator</role>
    <affiliation>INN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Investigacion Nutricional</name>
      <address>
        <city>Lima</city>
        <zip>1506</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biofortification</keyword>
  <keyword>Staple crops</keyword>
  <keyword>Stable isotope studies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

